Lupus & antiphospholipid syndrome
Association of Daily Glucocorticoid Dose With Worse Patient-Reported Outcomes in Systemic Lupus Erythematosus: Data From the Almenara Lupus Cohort
Authors' conclusion
The daily GC dose is associated with worse PROs in patients with SLE in LLDAS, even after adjusting for possible confounders.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) who have achieved Lupus Low Disease Activity State (LLDAS), single-centre cohort (Almenara Lupus Cohort)
- Participants
- 324 patients1,338 LLDAS visits
- Exposure
- Daily glucocorticoid (GC) dose and patient-reported outcomes (PROs)
- Outcome
- PROs: FACIT-F, LupusQoL, SF-36 physical and mental component summary scores, LFA-REAL PRO
Methodological detailssingle-centre, generalized estimating equations, multivariable-adjusted
- Single-centre
- Generalized estimating equations
- Multivariable-adjusted
Main finding
As reported in the abstract
PROs by daily GC dose (adjusted)
- Daily GC dose associated with worse scores in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) PRO, and 4 of the 8 Lupus Quality of Life (LupusQoL) domains (adjusted)
Observational data: associations, not effects.
Further findings
PROs by prednisone dose category (alternative analysis, adjusted)
- High GC dose category: trend of worse PRO scores; lower GC dose category: trend of better PRO scores
Original publication
Association of Daily Glucocorticoid Dose With Worse Patient-Reported Outcomes in Systemic Lupus Erythematosus: Data From the Almenara Lupus Cohort. J Rheumatol. Published 1 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →